BioPharma Dive September 30, 2024
Jonathan Gardner

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

Dive Brief:

  • Roche on Monday agreed to pay $850 million to acquire two experimental breast cancer drugs being developed by China-based biotechnology startup Regor Therapeutics.
  • The deal hands Roche two medicines that Regor, in a statement, described as “next-generation” versions of the CDK inhibitors widely used to treat certain breast cancers. One prospect is in early-stage testing already, while the other is ready to begin its first human trials. In a presentation to investors, Roche executives revealed early data showing one of the drugs, RGT-419B, has “durable single agent activity” in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Related Articles:
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry

Share This Article